Compass Therapeutics, Inc.

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to harnessing the power of the immune system to combat cancer and other serious diseases. The primary focus of Compass Therapeutics is on the development of next-generation monoclonal antibodies, with an innovative approach that combines these antibodies with other therapeutic modalities to create synergistic effects. The company operates within the biotechnology and healthcare sector, wielding a significant potential impact on the treatment of various cancers. By leveraging a proprietary scientific platform, Compass Therapeutics aims to discover and develop novel therapeutics that could transform the standard of care in oncology. Within the financial market, Compass Therapeutics represents a segment of the emerging biotech space, where cutting-edge research and clinical trials play a critical role in determining market performance and investor interest. Founded with a mission to solve complex medical challenges, Compass Therapeutics continues to advance its pipeline through rigorous research, underscoring its commitment to improving patient outcomes.